{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:55:15Z","timestamp":1791860115719,"version":"4.3.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Mammalian target of rapamycin inhibitors (mTORi), sirolimus (SRL) and everolimus (EVR), have distinct pharmacokinetic\/pharmacodynamics properties. There are no studies comparing the efficacy and safety of de novo use of SRL versus EVR in combination with reduced-dose calcineurin inhibitor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This single-center prospective, randomized study included first kidney transplant recipients receiving a single 3\u2009mg\/kg antithymocyte globulin dose, tacrolimus, and prednisone, without cytomegalovirus (CMV) pharmacological prophylaxis. Patients were randomized into 3 groups: SRL, EVR, or mycophenolate sodium (MPS). Doses of SRL and EVR were adjusted to maintain whole blood concentrations between 4 and 8\u2009ng\/mL. The primary endpoint was the 12-mo incidence of the first CMV infection\/disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>There were 266 patients (SRL, n\u2009=\u200986; EVR, n\u2009=\u200990; MPS, n\u2009=\u200990). The incidence of the first CMV event was lower in the mTORi versus MPS groups (10.5% versus 7.8% versus 43.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.0001). There were no differences in the incidence of BK polyomavirus viremia (8.2% versus 10.1% versus 15.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.360). There were no differences in survival-free from treatment failure (87.8% versus 88.8% versus 93.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.421) and incidence of donor-specific antibodies. At 12 mo, there were no differences in kidney function (75\u2009\u00b1\u200923 versus 78\u2009\u00b1\u200924 versus 77\u2009\u00b1\u200924\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.736), proteinuria, and histology in protocol biopsies. Treatment discontinuation was higher among patients receiving SRL or EVR (18.6% versus 15.6% versus 6.7%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.054).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>De novo use of SRL or EVR, targeting similar therapeutic blood concentrations, shows comparable efficacy and safety. The reduced incidence of CMV infection\/disease and distinct safety profile of mTORi versus mycophenolate were confirmed in this study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004749","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T04:01:03Z","timestamp":1690862463000},"page":"261-275","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial"],"prefix":"10.1097","volume":"108","author":[{"given":"Juliana","family":"Toniato de Rezende Freschi","sequence":"first","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."},{"name":"Nephrology Division, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Pontello","family":"Cristelli","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Almeida","family":"Viana","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Nunes","family":"Ficher","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Rika","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Proen\u00e7a","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmim Cardoso","family":"Dreige","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Marco","sequence":"additional","affiliation":[{"name":"Immunogenetics Institute, Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gerbase","family":"de Lima","sequence":"additional","affiliation":[{"name":"Immunogenetics Institute, Associa\u00e7\u00e3o Fundo de Incentivo \u00e0 Pesquisa, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Demarchi","family":"Foresto","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Ferreira","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."},{"name":"Urology Division, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Medina-Pestana","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."},{"name":"Nephrology Division, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"Tedesco-Silva","sequence":"additional","affiliation":[{"name":"Hospital do Rim, Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."},{"name":"Nephrology Division, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses.","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation.","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors.","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study.","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/FTD.0000000000000790","article-title":"Immunosuppressive drug-associated adverse event profiles in de novo kidney transplant recipients receiving everolimus and reduced tacrolimus doses.","volume":"42","author":"Miranda","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/ajt.14090","article-title":"Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data.","volume":"17","author":"Qazi","year":"2017","journal-title":"Am J Transplant"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials.","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different.","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","article-title":"Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.","volume":"31","author":"Shihab","year":"2014","journal-title":"Transpl Immunol"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.3389\/fimmu.2018.02953","article-title":"Selective effects of mTOR inhibitor sirolimus on na\u00efve and CMV-specific T cells extending its applicable range beyond immunosuppression.","volume":"9","author":"Bak","year":"2018","journal-title":"Front Immunol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation.","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell\u2013mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/TP.0000000000003124","article-title":"The influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis.","volume":"104","author":"de Paula","year":"2020","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"e13467","DOI":"10.1111\/tid.13467","article-title":"A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: combining the best of two options?","volume":"23","author":"Hellemans","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1097\/TP.0000000000004251","article-title":"The mycophenolate-based immunosuppressive regimen is associated with increased mortality in kidney transplant patients with COVID-19.","volume":"106","author":"Requi\u00e3o-Moura","year":"2022","journal-title":"Transplantation"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1097\/TP.0000000000004219","article-title":"The fourth dose of CoronaVac vaccine results in a small increase of seroconversion and antibody values among kidney transplant recipients.","volume":"106","author":"Cristelli","year":"2022","journal-title":"Transplantation"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ajt.13541","article-title":"BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12.","volume":"16","author":"Hirsch","year":"2016","journal-title":"Am J Transplant"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tid.12601","article-title":"Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.","volume":"18","author":"Pascual","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/tri.13478","article-title":"Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.","volume":"32","author":"Ferreira","year":"2019","journal-title":"Transpl Int"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000475888","article-title":"Donor-specific anti-human leukocyte antigens antibodies, acute rejection, renal function, and histology in kidney transplant recipients receiving tacrolimus and everolimus.","volume":"45","author":"Ferreira","year":"2017","journal-title":"Am J Nephrol"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/TP.0000000000003714","article-title":"Long-term efficacy and safety of everolimus versus mycophenolate in kidney transplant recipients receiving tacrolimus.","volume":"106","author":"Nunes Ficher","year":"2022","journal-title":"Transplantation"},{"key":"R29-20250604","article-title":"TMA in kidney transplantation.","author":"Imanifard","journal-title":"Transplantation"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vhri.2017.08.009","article-title":"Cost-effectiveness analysis of everolimus versus mycophenolate in kidney transplant recipients receiving no pharmacological prophylaxis for cytomegalovirus infection: a short-term pharmacoeconomic evaluation (12 months).","volume":"14","author":"Felipe","year":"2017","journal-title":"Value Health Reg Issues"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:20:46Z","timestamp":1749061246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004749","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}